四川至善唯新生物科技有限公司

Zhishan Weixin is a clinical-stage biotechnology company headquartered in Chengdu, China, dedicated to the development of adeno-associated virus (AAV) mediated gene therapies. The company focuses on treating rare genetic disorders, particularly in the fields of hematology and metabolic diseases. Its proprietary technology platform includes advanced AAV capsid engineering and promoter optimization to enhance therapeutic efficacy and safety. Zhishan Weixin's lead program, ZS801, is a gene therapy for Hemophilia B currently undergoing clinical evaluation. With an integrated approach encompassing research, clinical development, and internal GMP manufacturing, the company aims to provide transformative treatments for patients with high unmet medical needs.